Cytokinetics Inc
(NAS:CYTK)
$
48.98
-10.25 (-17.31%)
Market Cap: 5.14 Bil
Enterprise Value: 5.27 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 43/100 Cytokinetics Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021 / 02:45PM GMT
Release Date Price:
$20.3
(+3.05%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
Good morning, and welcome to day 3 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. I am pleased to welcome Cytokinetics to join me in the next virtual fireside chat. We recently initiated on the company, and they are entering a defining period with a key Phase II readout forthcoming on CK-274 while they're also beginning to gauge with regulators on omecamtiv after positive Phase III data late last year.
Joining -- representing the company is CEO, Robert Blum. Robert, welcome. Thanks for joining us. I believe you're going to start with some opening comments.
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director
Yes. Thank you, Carter. Thanks for inviting us. I'll share my slides. Tell me if you can see that okay.
Carter Lewis Gould;Robert I. Blum
Barclays Bank PLC, Research Division - Senior Analyst;
Great.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot